Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer



Status:Recruiting
Conditions:Obesity Weight Loss
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:19 - Any
Updated:10/7/2018
Start Date:September 8, 2017
End Date:September 8, 2021
Contact:Christina Dieli-Conwright, PhD
Email:cdieli@usc.edu
Phone:323-442-2180

Use our guide to learn which trials are right for you!

Endometrial Cancer and Obesity: An Exercise and Diet Intervention for Weight Loss

This pilot clinical trial studies exercise and diet intervention in promoting weight loss in
obese patients with stage I endometrial cancer. Exercise and diet may cause weight loss and
minimize the risk of gynecologic surgery related to being overweight in patients with
endometrial cancer.

PRIMARY OBJECTIVES:

I. To determine if participation in a 16-week exercise and diet intervention would elicit
weight loss, assessed by a 10% decrease in fat mass, in endometrial cancer (EC) patients.

SECONDARY OBJECTIVES:

I. To determine if participation in a 16-week exercise and diet intervention would improve
cardiorespiratory fitness (CRF) and muscular strength.

TERTIARY OBJECTIVES:

I. To determine if participation in a 16-week exercise and diet intervention could improve
quality of life (QOL), fatigue, and depression.

II. To determine the effects of a 16-week exercise and diet intervention on cardiovascular
(CV) health.

OUTLINE:

Patients undergo aerobic exercise thrice weekly over 95 minutes for up to 16 weeks. Patients
also undergo multi-lifestyle interventions based on the dietary approaches to stop
hypertension (DASH) diet once weekly over 1 hour for up to 16 weeks.

After completion of study, patients are followed up for 16 weeks.

After completion of study, patients are followed up for 16 weeks.

Inclusion Criteria:

- Clinical stage I EC

- Low grade disease positive for estrogen and progesterone receptors

- Body mass index (BMI) >= 30 kg/m^2

- No history of any musculoskeletal, cardiorespiratory or neurological diseases that
preclude the participation in exercise

- Self ambulatory and without use of assistive walking devices

- Is not a candidate for immediate hysterectomy, following evaluation by a physician,
due to desire to preserve fertility, due to degree of obesity, due to comorbidities,
or due to patient refusal of hysterectomy

- Must agree to take progestin agents (i.e., oral agents or MIRENA intrauterine device
[IUD] which are accepted treatments for low grade uterine malignancies to control
their disease while the intervention is ongoing)

- Note: potential participants WILL NOT be asked to delay surgery to participate in
this pilot study

Exclusion Criteria:

- Patients with metastatic disease

- BMI =< 29.9 kg/m^2

- History of any musculoskeletal, cardiorespiratory or neurological diseases that
preclude the participation in exercise

- Is not self ambulatory and relies on the use of assistive walking devices

- Is a candidate for immediate hysterectomy, following evaluation by a physician

- In judgement of a physician, is not a candidate for progestin agents
We found this trial at
1
site
1441 Eastlake Ave
Los Angeles, California 90033
(323) 865-3000
Principal Investigator: Christina Dieli-Conwright, PhD
Phone: 323-442-2905
U.S.C./Norris Comprehensive Cancer Center The USC Norris Comprehensive Cancer Center, located in Los Angeles, is...
11
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials